A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.
This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.
Biomea Fusion (BMEA) is the sponsoring company for this trial. BiotechSign currently grades this company F (29/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.